BioSpace News Archive

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, reported financial results for the third quarter of 2019 and provided an update on regulatory activities related to Vicinium.

AVEO Oncology reported financial results for the third quarter ended September 30, 2019 and provided a business update.

IVERIC bio, Inc. provided further details of the recently announced clinical trial results for the Company’s Zimura® program in geographic atrophy secondary to dry age-related macular degeneration, reviewed the Company’s financial results for the third quarter 2019 and provided a general business update.

Precision BioSciences, Inc., a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.

Stone Street Group has announced it has initiated coverage on BiomX Inc

Kura Oncology, Inc. announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present at the Stifel Healthcare Conference on Tuesday, November 19, 2019 at 1:15 p.m. ET / 10:15 a.m. PT.

Strongbridge Biopharma plc announced that John H. Johnson, executive chairman, will present at the Stifel 2019 Healthcare Conference and the Evercore ISI 2nd Annual HealthCONx Conference.

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported financial results for the third quarter ended September 30, 2019 and highlighted recent progress and upcoming milestones for its pipeline programs.

200-patient painful diabetic peripheral neuropathy study and 300-patient fibromyalgia study build on previous compelling data obtained in these indications

Fortress Biotech, Inc., an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, announced financial results and recent corporate highlights for the third quarter ended September 30, 2019.